Key result
Transcatheter therapies, including TAVR for low-risk patients and MitraClip for functional mitral regurgitation, have expanded treatment options for valvular heart disease.
Why the study?
A recent influx of transformational therapeutic options has emerged in valvular heart disease, warranting a review of landmark trials shaping modern management.
Recent landmark trials have expanded the indications for transcatheter therapies like TAVR and MitraClip in patients with valvular heart disease.
Broadens TAVR access for low-risk patients; extends prior high-risk trial evidence.
PURPOSE OF REVIEW: In recent years, no other field of cardiology has experienced a greater influx of transformational therapeutic options as valvular heart disease. The present review discusses the landmark trials published in the last 18 months that have shaped the modern day management of valvular heart diseases. RECENT FINDINGS: There have been several landmark trials in recent years, which have expanded the indications for transcatheter aortic valve replacement to low-risk surgical patients and the use of MitraClip for patients with functional mitral regurgitation. Options for transcatheter management of right-sided valvular disease also continue to evolve, including promising results from early feasibility studies. SUMMARY: The development of novel transcatheter therapies for valvular heart disease has expanded the armamentarium of physicians treating patients with valvular heart disease. The present review will focus on the recent (within 2 years) trials in this field of interest.
No takes yet. Share an insight, caveat, or question.
Goel et al. (2020) conducted a review in valvular heart diseases. Transcatheter therapies was evaluated. Transcatheter therapies, including TAVR for low-risk patients and MitraClip for functional mitral regurgitation, have expanded treatment options for valvular heart disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: